Under th

PTO/SB/21 (07-06)  Approved for use through 09/30/2006. OMB 0651-0031  U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.	Im
ne Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.	
40/500 004	

Application Number		10/586,831			
61P FRANSMITTAL		Filing Date	July 19, 2006		
/ %FORM		First Named Inventor	Philippe Renaud		
FEB 1 6, 2007		Art Unit	Not Yet Assigned		
correspondence after initial filing)		Examiner Name	Not Yet Assigned		
Total National Pages in This Submission 5		Attorney Docket Number	034299-707		
	ENCLO	SURES (check all that apply)	<b>.</b>		
Fee Transmittal Form		☐ Drawing(s) ☐ After Allowance Communication to TC		owance Communication to TC	
Fee Attached	Licensing	Licensing-related Papers  . Appeal Communication to Board of Appeals and Interferences			
Amendment / Reply	Petition	Petition  Appeal Communication to TC  (Appeal Notice, Brief, Reply Brief)			
After Final	_	Petition to Convert to a Provisional Application Provisional Application		ary Information	
Affidavits/declaration(s)		☐ Power of Attorney, Revocation Change of Correspondence Address ☐ Status Letter		etter	
Extension of Time Request	☐ Terminal	☐ Terminal Disclaimer ☐ Other Enclosure(s) (please identify below):		• '	
	1 — ·	for Refund	Eight (8) Ref	erences Cited; Postcard.	
Express Abandonment Request CD		ber of CD(s)			
Information Disclosure State	ement	ndscape Table on CD			
Certified Copy of Priority Document(s)	Remarks				
Reply to Missing Parts/					
Incomplete Application					
Reply to Missing Parts under 37 CFR1.52 or 1.	53				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm	THELEN REID	BROWN RAYSMAN & STEINER			
Signature	()/w	19/W	2		
Printed Name	Robert E. Krebs	5			
Date	Date [3 Feb. 2007 Reg. No. 25,885]				
	CERTIFICA	TE OF TRANSMISSION/MAI	LING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.					
Signature	sanua /	Jalla)		<i>j</i> ·	
Typed or printed name	eneva Walls		Date	2-14-07	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLEANT:

Phillippe Renaud et al.

CONFIRMATION NO.: Not Yet Assigned

SERIAL NO.:

10/586,831

FILING DATE:

July 19, 2006

TITLE:

Dispensing Device For Microfluidic Droplets Especially For Cytometry

**EXAMINER:** 

Not Yet Assigned

ART UNIT:

Not Yet Assigned

## **CERTIFICATE OF MAILING**

I hereby certify that this paper is being deposited with the United States Postal Service as Express Mail in an envelope addressed to: Mail Stop Amendment Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date printed below:

Date:

2-14-07

me://////
@neva Walls

Mail Stop: AMENDMENT

**COMMISSIONER FOR PATENTS** 

P.O. Box 1450

**ALEXANDRIA, VA 22313-1450** 

## INFORMATION DISCLOSURE STATEMENT

In compliance with the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicant hereby submits this Information Disclosure Statement (IDS) including a Form PTO-1449 containing a list of references which may be material to the examination of the above-referenced application. This submission is not to be construed as a representation that a prior art search has been conducted, that additional information material to the examination of this application does not exist, or that any one or more of the listed references constitutes prior art.

The Examiner is urged to carefully consider this Information Disclosure Statement and all the listed references, and to indicate same by initialing the appropriate portion(s) of the Form PTO-1449 and forwarding an initialed copy to applicant.

I

This statement is filed pursuant to (CHECK ONE BOX):

37 C.F.R. § 1.97(b). This information disclosure statement is filed either: (1) within three months of the filing date of a national application other than a continued prosecution application under §1.53(d); (2) within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; (3) before the mailing date of a first office action on the merits; or (4) before the mailing of a first office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114, whichever event occurs last. Accordingly, this information disclosure statement requires no fee and no certification. 37 C.F.R. § 1.97(c). This information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97(b), but before the mailing date of any of the following: (1) a final action under 37 C.F.R. § 1.113; (2) a notice of allowance under 37 C.F.R. § 1.311; or (3) an action that otherwise closes prosecution in the application. Accordingly, this information disclosure statement requires either: (1) the fee specified in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under 37 C.F.R. § 1.97(c); or (2) a certification according to 37 C.F.R. § 1.97 (e)(1) or (2).

## 37 C.F.R. § 1.97(d).

This information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97 (c).

Accordingly, this information disclosure statement requires:

- (1) a certification in accordance with 37 C.F.R. § 1.97(e); and
- (2) the fee specified in 37 C.F.R. § 1.17 (p) to consider an information disclosure statement under 37 C.F.R. § 1.97(d).

If this statement crosses in the mail with an office action, or is otherwise not in the indicated category of 37 C.F.R. § 1.97, it is respectfully requested that this statement be treated in the next appropriate category and made of record. To the extent required, please treat this paper as a conditional petition for acceptance of the information disclosure statement.

II

F	ees Due (CHECK ONE BOX):
	No fee is due.
	The fee specified in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under 37 C.F.R. § 1.97(c) or 37 C.F.R. § 1.97(d) is enclosed (\$180).
	III
C	Certification (CHECK ONE BOX):
	No certification is necessary.
	Pursuant to 37 C.F.R. § 1.97(e)(1), the undersigned hereby certifies:  That each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
	Pursuant to 37 C.F.R. § 1.97(e)(2), the undersigned hereby certifies:  No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this information disclosure statement.
P	lease charge any additional required fee or credit any overpayment to our deposit account number 50-1698.
	Respectfully submitted, THELEN REID BROWN RAYSMAN & STEINER LLP
Dated: I	February 13, 2007  Robert E. Krebs  Reg. No. 25,885

THELEN REID BROWN RAYSMAN & STEINER LLP

P.O. Box 640640

San Jose, CA 95164-0640

Tel: (408) 292-5800 Fax: (408) 287-8040

Serial No. Atty. Docket No. Form PTC 034299-707 Department of Commerce 10/586,831 (Rev. 2-32) Patent and Trademark Office Applicant: Philippe Renaud Information Disclosure Statement by Applicant Filed: Group: (Use several sheets if necessary) July 19, 2006 Not Yet Assigned **U.S. Patent Documents** Subclass Class Filing Date Document No. Name Date Init. 435 288.3 09-14-2001 A 2002/0058332 A1 Quake et al. 05-16-2002 422 100 02-08-2001 В Fuhr et al. 2003/0108452 A1 06-12-2003 09-25-2003 547 C 204 Gawad et al. 2003/0178310 A1 09-25-2003 **Foreign Documents** Translation Class Subclass Yes No Document No. Date Country Init. 06-06-2002 D WO 02/44319 A2 07-11-2002 WO 02/054044 A2 **PCT** E 08-13-03 1335198 A1 F EP Other Documents (Including Author, Title, Date, Pertinent Pages, etc.) International Preliminary Seach Report, PCT/FR2005/050025, 6 pgs, (01-017-2005). G S. GAWAD et al., "Micromachined Impedance Spectroscopy Flow Cytometer For Cell Analysis And H Particle Sizing", LAB on A Chip, 2001, Pgs 76-82 (08-13-2001). Date Considered Examiner Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FEB 1 6 2007